-
About Me
Alison Bass is a Pulitzer Prize nominee and author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, which won the NASW Science in Society Award. She was a longtime medical and science writer for The Boston Globe and has also written for The Miami Herald, Psychology Today and MIT's Technology Review, among other publications. A series she wrote for The Boston Globe on psychiatry was nominated for a Pulitzer Prize and she has received many other journalism awards. In 2007, she won a prestigious Alicia Patterson Fellowship to write Side Effects. Bass teaches journalism at Mount Holyoke College and Brandeis University.
Monthly Archives: September 2012
Falsely inflated statistics about sex trafficking in the U.S. make bad policy and laws
Share Wasn’t it Mark Twain who said that a lie can travel halfway around the world while the truth is still putting on its shoes? I thought of his famous quote when my husband passed along a link he had … Continue reading
Why West Virginia has second highest rate of prescription drug overdoses in the nation
Share Did you know that West Virginia has the second highest rate of deaths from prescription drug overdoses in the country? I didn’t, until I moved to the Mountain State to live and work and became curious as to what … Continue reading
Posted in antidepressants, antipsychotic drugs, drug marketing, health care costs, patient care, pharmaceutical industry, prescription drug overdoes, public health
Tagged CDC, Charleston Gazette, drug commercials, Massachusetts, Oxycontin, prescription drug overdoses, universal health care, West Virginia, West Virginia University
5 Comments
Martin Keller, principal investigator of Paxil study 329, retires from Brown University
Share I just learned that Dr. Martin Keller, principal investigator of the controversial Paxil study 329, has retired from his position as a professor of psychiatry at Brown University — see here. As Pharmalot notes, Keller quietly retired June 30 in … Continue reading
Calls for action against authors of controversial Paxil study are getting louder
Share In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the … Continue reading
Posted in antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
Tagged antidepressants, Brown University, Department of Justice, GlaxoSmithKline, Health Care Renewal, Martin Keller, oneboringoldman, Paxil
2 Comments